The first randomized trial of ketamine combined with CAMS therapy is set to begin at the Cleveland Clinic in early 2021. This study will focus on reducing suicidality in adolescents and young adults. According to the researchers, “ketamine is effective in the short term, but the period of transition after discharge is very risky.” In this study, patients will be given acute medical therapy, as well as weekly CAMS sessions for long-term management. The goal is that by combining ketamine with CAMS therapy the patients will have the resources they need to take care and protect themselves against further suicide attempts.
Read the entire article from Consult QD: First Randomized Trial of Ketamine for Youth Suicidality to Launch With NIH Support
At CAMS-care, we offer suicide assessment and prevention training, consulting, and resources. For more information on CAMS, please contact us.